AEON Biopharma (AEON) Cash from Financing Activities (2021 - 2025)

AEON Biopharma has reported Cash from Financing Activities for 5 years, with the latest figure at $1.8 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 1746.39% year-over-year to $1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.3 million (up 34.05% YoY) and the FY2025 annual result came in at $20.3 million, up 34.05% from the prior year.
• Cash from Financing Activities rose to $1.8 million in Q4 2025 per AEON's latest filing, from $84000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $278.0 million in Q1 2021 and troughed at -$4.0 million in Q4 2022.
• A 5-year average of $24.3 million and a median of $97000.0 in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities plunged 114120.31% in 2022, then jumped 1746.39% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$3495.0 in 2021, then slumped by 114120.31% to -$4.0 million in 2022, then soared by 250.3% to $6.0 million in 2023, then slumped by 98.38% to $97000.0 in 2024, then surged by 1746.39% to $1.8 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.8 million, $84000.0, and $84000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.